business Thank you, call. update quarter today Alex, second and thank our you, us everyone, for for joining
cancer overcome on cancer They normal to as which therapy ability treatments. gain survive therapies, by start the referred evade their strategy, to our is scientific they resistance proteins us lose an as effectiveness. cancer explaining cancer to resistance business eventually the Let cells over help cells. pro-survival central to proteins cells and Cancer cancer and to of advantage to often are which
effective Bcl-X Suppressing is, and Mcl-X a such to members including family, itself as of therefore, pro-survival promising create therapies. Bcl-X strategy more the proteins,
enhance strategy our order is candidates combine and approved effectiveness. drugs restore business their to in Our to with
elevated combination is inhibitor and a It analog. often approved first agent is first CLL indicated with the the and the for second-line venetoclax, an in race a responding Bcl-X a drugs or bring Venetoclax with of to combination community eventually a is in advance. or important them example, stop amplification. lot is Mcl-X These this correlated levels that For in suppress findings scientific with venetoclax. AML, ongoing attracted using hypomethylating competitive therapeutic patients attention aim have to first-line treated or with market of nucleoside Mcl-X and
CDK relapsed combination supported of demonstrated of patients separately is studies, tolerable CYCXXX multiple that and leader clinical of the a CYCXXX, resistance. studies Cyclacel is cells. Bcl-X our inhibitor patients treating Mcl-X that enhances refractory X cancer showing suppression simultaneous this with believe relapsed or the combination X/X durable in has preclinical In AML venetoclax. strategy and solid tumors. cell CLL of problem doses We to are MDS apoptosis suppression in with in refractory This race address death a or we at and cancer Mcl-X with or by hit program double
the Bcl-X test refractory applying both CYCXXX pressure can with Mcl-X to with hypothesis designed are that or cancers. and antitumor studies meaningful clinical Our relapsed against have by effects venetoclax on
level study the report First-in-Human agent fourth of as to CYCXXX single anticancer of to our In of a as previously and a treatments X was that X its after excited treated has Mcl-X XXX-XX endometrial of part CYCXXX are found achieved We have the shrinkage tumor dose agent, escalation cycles single on activity milligrams. XXX in with patient compound. cancer a dose of I amplification was study Phase
the dosing anticancer per infusions of X X-week week over for weeks from a days of This schedule is X X-hour frequent the out administered of of cycle. activity evidence first CYCXXX
CYCXXX a study, the As X-hour X a once every infusion administered over X weeks. reminder, part of was in
completion patients of XXX-XX for In aim protocol open X previously with who which X part has have Following are with of continuing the the enrolled CLL CYCXXX XXX-XX CYCXXX, study, of the front-line with and combination cycles, oral been pharmacokinetics. of dosing approval the or ibrutinib relapsed X and on of formulation treatment and failed evaluating tolerated. therapy of an development oral the refractory X well was respectively, venetoclax, CYCXXX for
of of venetoclax is the that relapse. leukemia in the evade main usually for cells issues nodes causing One CLL the lymph eventual effects
disease advance to patients lymph forward reporting available. an these combination will important the as of be node from they CYCXXX become and updates CLL. cure by look Eradicating towards We venetoclax of
to Based in on sites to the we're several additional so. or next hospitals with discussions advanced from in expect sites open quarter further study, interest participate this in and
our combination progress I with announced to other Turning first MDS. protocols, patients AML that XXX-XX, Phase venetoclax CYCXXX we in with recently treated the a evaluating refractory patient with relapsed have operating or or we study, in in
a inducing of and is study plays role. overexpression adjusting the confirming The for respectively, may and than both supported evidence for in main in either alone. apoptosis more hit is preclinical feature, Bcl-X dominant a AML Bcl-X, beneficial where suppressing double of be CYCXXX by protein venetoclax CLL, Unlike the this Mcl-X Mcl-X synergy rationale suppression
with safety in evaluating Association patients our During Phase published nucleoside I/II combination the dosed the of combination the and effectiveness announced data have X and oral quarter, or sapacitabine we the a inhibitors analog, MDS Part that refractory relapsed been or Bcl-X of AML. Hematology XXX-XX study first in European sapacitabine of at in of combination with venetoclax. Congress clinical supports XXth AML an The
in failed regimen venetoclax for is hypomethylating combination approved. Venetoclax offer such and active or clinical relapsed in agents. hypomethylating approval with accelerated MDS refractory as is already therapy investigations, prior AML has or cytarabine. frontline treatment therapy as AML, Based remissions venetoclax on an to with who or sapacitabine therapy, in therefore, Combining is cytarabine and effective that while prior induces complete have front-line patients oral agents sapacitabine may,
PLK CYCXXX being with Patients escalation as patients I in leukemias. recruited X Phase agent dose a single First-in-Human a are advanced XXX-XX to inhibitor study, our of
first squared, observed limiting dosed target respectively. meter intravenous activity has inhibitor CYCXXX XX inhibition and The thus X have that selective dose xenograft high a models human far. demonstrated milligrams been have patients X per is small CYCXXX doses the and potent starting No of PLK in and cancer. been at selective molecule XX of toxicities
patients objective alliance X of XXX-XX, but remains studies candidates of MD XXX-XX hematological strategic and All Cyclacel these XXX-XX, the evaluating Cyclacel of Cancer our Under Center alliance, MD XXX-XX, the of X with of patient are terms in Anderson malignancies. costs part sponsor the with with assumes Anderson the studies.
of enhance in to mutations of such those HR-deficient disease survival. our inhibitors, targeting the standard recombination second for mutant benefit damaged inherited control the or efficacy care cancers, care clinical gynecological to of by Let us now with to turn DNA pathways, include extend duration homologous in strategy which BRCA modest BRCA standard combination cancers suggest and a to The used approved drugs PARP of novel improve need mutations. for as
an than on relevant from to HR-deficient action demonstrated Sapacitabine of drug Sapacitabine is that mechanism of patient has including BRCA-positive inhibitors. works more the as distinct X durable a years. still PARP mechanism breast in by cancer, activity
combination XXXX clinical at investigator is AstraZeneca naïve of data sapacitabine the the AACR ovarian breast provides olaparib leading ongoing cancer reported Cyclacel sapacitabine inhibitor Recent Institute. Dana-Farber an Cancer and sponsor dosed for the for orally at IST olaparib, PRAP for is enrolling breast with IST PARP The sponsor approved supplying sapacitabine respectively. BRCA-mutant of the with Department Breast patients study and or and and Cancer are the inhibitor cancer. and rational
partial X response patients, patients total X a of to treatments. been BRCA-mutant investigators, continuing PR. According or the Two and treated cancer, achieved have has are the on breast patient
Phase In data AML from our from I CYCXXX milestones strategy Report or advance our studies or patients sapacitabine the Phase the summary, dosing data report Phase venetoclax formulation Report solid Report data report or initial schedule cancers, I relapse an leukemias. initial data the in the report leukemias. advanced in when patients AML pathway initial of frequent cancer relapsed sapacitabine study to data on of execute Phase as trial elderly Olaparib from relapsed in combination breast with I/II by of with metastatic Ib/II and submissibility in with and and from CYCXXX study from in regulatory the MDS. BRCA-mutant of Phase we CYCXXX, First-in-Human updated venetoclax patients. determine with study the oral continue development data reported includes, CYCXXX I in initial I refractory sapacitabine refractory clinical investigators programs, key our Phase IST refractory patients
to of we studies. XXXX, capital estimated resources milestones the clinical us have ongoing until clinical in With through take our key the hand, end on
second like review I quarter turn would to call Paul now XXXX over to the our financials. Paul? to
